Summary
Five volunteers with normal ovarian cycles received oral doses of 2×2.5 mg or 3×2.5 mg bromocriptin (CB 154)/day respectively. The treatment started at the onset of menstruation and lasted one complete cycle. In addition to the decrease of prolactin secretion, a reduction of plasma progesterone concentrations during the corpus luteum phase was demonstrated. This fall of progesterone seemed to be preferentially due to bromocriptin-induced hypoprolactinaemia and not to direct ovarian effects of the drug.
Zusammenfassung
Fünf freiwillige, eine normale Ovarialfunktion aufweisende, gesunde Versuchspersonen erhielten täglich 2×2,5 mg bzw. 3×2,5 mg Bromokriptin oral verabfolgt. Die mit Menstruationsbeginn einsetzende Behandlung wurde über die gesamte Zykluslänge durchgeführt. Neben einer eindeutigen Hemmung der hypophysären Prolaktin-Sekretion konnte eine statistisch signifikante Reduktion der Progesteron-Plasmakonzentration während der Corpus luteum-Phase beobachtet werden. Die bisherigen Resultate sprechen dafür, daß dieser Progesteron-Abfall vorzugsweise der Bromokriptin-induzierten Hypoprolaktinämie und weniger einer direkten ovariellen Wirkung des getesteten Pharmakons anzulasten ist.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Besser, G. M., Parke, L., Edwards, C. R. W., Forsyth, I. A., McNeilly, A. S.: Galactorrhea: successful treatment with reduction of plasma prolactin levels by bromo-ergocryptine. Brit. Med. J.3, 669 (1972)
Del Pozo, E., Brun Del Re, R., Varga, L., Friesen, H.: The inhibition of prolactin secretion in man by CB 154 (2-br-alpha-ergocryptine). J. Clin. Endocrinol. Metab.35, 768 (1972)
Del Pozo, E., Goldstein, M., Friesen, H., Brun Del Re, R., Eppenberger, U.: Evidence for the lack of action of prolactin in the regulation of the human menstrual cycle. Am. J. Obstet. Gynecol.123, 719 (1975)
Del Pozo, E., Varga, L., Schulz, K.-D., Künzig, H. J., Marbach, P., Lopez Del Campo, G., Eppenberger, U.: Pituitary and ovarian response patterns to stimulation in the postpartum and in galactorrhea-amenorrhea. Obstet. Gynecol.46, 539 (1975)
Del Pozo, E., Wyss, H., Lancranjan, I., Obolensky, W., Varga, L.: Prolactin-induced luteal insufficiency and its treatment with bromocriptin: preliminary results. Proceedings of the Symposium on Ovulation in the Human, Freiburg, September 1975 (ed. P. G. Crosignani). Academic Press (in press)
Delvoye, P., Taubert, H.-D., Jürgensen, O., L'Hermite, M., Delogne, J., Robyn, C.: Influence of circulating prolactin increased by a psychotropic drug on gonadotrophin and progesterone secretion. Acta endocr. (Kbh.) Suppl.184, 110 (1974)
Geiger, W.: Radioimmunologische Bestimmungen von HCG, HCS, STH und TSH. Fortschr. Geb. Gynäk.52, 1 (1974)
Hwang, P., Guyda, H., Friesen, H.: A radioimmunoassay for human prolactin. Proc. Acad. Sci.68, 1902 (1971)
Künzig, H. J., Geiger, W., Schulz, K.-D., Lose, K. H.: Treatment of galactorrhea-amenorrhea syndrome with 2-Br-alpha-ergocryptine (CB 154): clinical response and pattern of pituitary and steroid hormones before and during therapy. Arch. Gynäk.218, 85 (1975)
McNatty, K. P., Sawers, R. S., McNeilly, A. S.: A possible role for prolactin in control of steroid secretion by the human Graafian follicle. Nature (Lond.)250, 653 (1974)
Schulz, K.-D., Del Pozo, E., Lose, K. H., Künzig, H. J., Geiger, W.: Successful treatment of mastodynia with the prolactin inhibitor bromocryptine (CB 154). Arch. Gynäk.220, 83 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schulz, K.D., Geiger, W., Del Pozo, E. et al. The influence of the prolactin-inhibitor bromocriptin (CB 154) on human luteal function in vivo. Arch. Gynak. 221, 93–96 (1976). https://doi.org/10.1007/BF00667138
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00667138